Claims
- 1. A method of treating or preventing prostate cancer in a male mammalian patient in need thereof, comprising administering to said patient a COX-2 selective inhibiting compound in an amount that is effective to treat or prevent prostate cancer.
- 2. A method of treating or preventing prostate cancer in accordance with claim 1 wherein the patient is a human.
- 3. A method in accordance with claim 2 wherein the COX-2 selective inhibiting compound is rofecoxib.
- 4. A method in accordance with claim 3 further comprising administering to the patient a 5-alpha reductase inhibitor.
- 5. A method in accordance with claim 3 wherein the 5-alpha reductase inhibitor is selected from the group consisting of: finasteride, dutasteride and epristeride.
- 6. A method of treating or preventing prostate cancer in a male mammalian patient comprising administering to the patient a COX-2 selective inhibiting compound in combination with radiation therapy.
- 7. A method in accordance with claim 6 wherein the radiation therapy comprises external radiation or radioactive seed implantation.
- 8. A method of treating or preventing prostate cancer in accordance with claim 3 wherein the COX-2 selective inhibiting compound is administered in combination with selenium.
- 9. A method of treating or preventing prostate cancer in accordance with claim 3 wherein the COX-2 selective inhibiting compound is administered in combination with vitamin C or E.
- 10. A method of treating or preventing prostate cancer in accordance with claim 3 wherein the COX-2 selective inhibiting compound is administered in combination with at least one drug selected from the group consisting of: alkylating agents, antibiotics, hormones, anti-hormones, LHRH analogs and antagonists, anti-metabolites and rniscellaneous anti-cancer agents.
- 11. A method of treating or preventing prostate cancer in accordance with claim 10 wherein the COX-2 selective inhibiting compound is administered in combination with at least one drug selected from the group consisting of:
Myleran® (busulfan), Platinol® (cisplatin), Alkeran® (melphalan hydrochloride), Cytoxan® (cyclophosphamide), Leukeran® (chlorambucil), BiCNU® (carmustine), CeeNUl® (lomustine [CCNU]), Mustargen® (mechloroethamine hydrochloride), Adriamycin® (doxorubicin hydrochloride), Blenoxane® (bleomycin sulfate), Cerubidine® (daunorubicin hydrochloride), Cosmegen® (dactinomycin), Mithracin® (plicamycin), Mutamycin® (mitomycin), Novantrone® (mitoxantrone hydrochloride), progesterone, estrogen, Estrace® (estradiol), DES, Casodex® (bicalutamide), Eulexin® (flutamide), Nilandrone® (nilutamide), Synarel® (nafarelin acetate), Lupron® (leuprolide acetate), Zoladex® (goserelin acetate), Histerelin®, ganirelix, cetrorelix , aberelix, Cytosar® (cytarabine), Fludura® (fludarabine phosphate), Leustatin® (cladribine), methotrexate, Purinethol® (mercaptopurine), thioguanine, Camptosar® (irinotecan hydrochloride), Celestone® (betamethasone), DTIC® (dacarbazine), Elspar® (asparaginase), Gemzar® (gemcitabine hydrochloride), Hexalen® (altretamine), Hycamtin® (topotecan hydrochloride), Hydrea® (hydroxyurea), interferon A, Navelbine® (vinorelbine tartrate), Oncaspar® (pegaspargase), Oncovin® (vincristine sulfate), Proleukin® (aldesleukin), Rituxan® (rituximab), Rimaxin®, Taxol® (paclitaxel) and Velban® (vinblastine sulfate).
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 60/178,722, filed on Jan. 28, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60178722 |
Jan 2000 |
US |